The proposed pilot study will provide safety and efficacy preliminary data regarding singular
and combined effects of two therapeutic approaches, intranasal insulin and treatment with the
sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic
and vascular dysfunction in adults with preclinical Alzheimer's disease (AD) and amnestic
mild cognitive impairment (aMCI) or early AD.